About Index Trending news
Lists
Pricing
Immunovaccine Inc.

Immunovaccine Inc.

Immunovaccine Inc.

Immunovaccine Inc. (TSX-V: IMV) develops vaccines, using its patented delivery platform – DepoVax™ – for therapeutic cancer and infectious diseases.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Post-IPO equity
$11,200,000
Employees

Team size

10+

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Immunovaccine Inc. makes some noise.